Literature DB >> 33475867

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.

Dana M Harris1, Fernando F Stancampiano2, M Caroline Burton3, Ann M Moyer4, Michael J Schuh5, Jose R Valery2, Yan Bi6.   

Abstract

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Gastroesophageal reflux disease; Helicobacter pylori; Pharmacogenomics; Proton pump inhibitors

Mesh:

Substances:

Year:  2021        PMID: 33475867     DOI: 10.1007/s10620-020-06814-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  2 in total

Review 1.  New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.

Authors:  M Robinson
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.

Authors:  John J Lima; Cameron D Thomas; Julia Barbarino; Zeruesenay Desta; Sara L Van Driest; Nihal El Rouby; Julie A Johnson; Larisa H Cavallari; Valentina Shakhnovich; David L Thacker; Stuart A Scott; Matthias Schwab; Chakradhara Rao S Uppugunduri; Christine M Formea; James P Franciosi; Katrin Sangkuhl; Andrea Gaedigk; Teri E Klein; Roseann S Gammal; Takahisa Furuta
Journal:  Clin Pharmacol Ther       Date:  2020-09-20       Impact factor: 6.903

  2 in total
  2 in total

1.  Dexlansoprazole prevents pulmonary artery hypertension by inhibiting pulmonary artery smooth muscle cell to fibroblast transition.

Authors:  Qian Jiao; Fangdi Zou; Shiliang Li; Jiawen Wang; Yunping Xiao; Zhihua Guan; Liang Dong; Jinwei Tian; Shengqing Li; Rui Wang; Jian Zhang; Honglin Li
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.

Authors:  Shuang Zhou; Ran Xie; Xiaodan Zhang; Xu He; Jie Huang; Yin Jungang; Man Liao; Ying Ding; Dandan Yang; Ying Liu; Qian Zhang; Guoping Yang; Fang Liu; Shengjiang Guan; Qing He; Honggang Lou; Fengyun Gong; Xianmin Meng; Qian Xiang; Xia Zhao; Yimin Cui
Journal:  Clin Transl Sci       Date:  2022-03-25       Impact factor: 4.438

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.